Pharmacokinetic-pharmacodynamic considerations in the design of Hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap!

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Ambrose, Paul G ^a,b   Bhavnani, Sujata M ^a,b   Ellis Grosse, Evelyn J ^c   Drusano, George L ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c E2g Biopharmaceutical Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CREATININE; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; ORITAVANCIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; HOSPITAL ACQUIRED BACTERIAL PNEUMONIA; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK REDUCTION; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STEADY STATE; VENTILATOR ASSOCIATED BACTERIAL PNEUMONIA; VENTILATOR ASSOCIATED PNEUMONIA; CLINICAL TRIAL (TOPIC); CROSS INFECTION; HOSPITAL; METHODOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HOSPITALS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 77955706083     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653057     Document Type: Conference Paper

References (21)

1. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
2. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008; 52(1):204-210.
3. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone AUC:MIC ratio and the probability of eradication of the infecting pathogen in patients with nos-ocomial pneumonia. J Infect Dis 2004; 189:1590-1597.
4. JMI Laboratories. SENTRY Antimicrobial Surveillance Program 2004-2008. http://www.jmilabs.com/presentations/default.cfm. Accessed 15 June 2010.
5. Craig WA. Pharamcokinetic-pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998; 26: 1-12.
6. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081.
7. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:24-36.
8. Captiano B, Mattoes HM, Shore, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycininolder adults. Chest 2004; 125:965-973.
9. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapul-monary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431-1434.
10. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46:586-589.
11. Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30:989-991.
12. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapul-monary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003; 31:2242-2243.
13. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharma-cokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32:2059-2062.
14. Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for the treatment of Staphylococcal pneumonia with ceftobiprole. An-timicrob Agents Chemother 2009; 53(8):3294-3301.
15. Fleishaker JC, McNamara PJ. Performance of a diffusional clearance model for b-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics. Antimicrob Agents Che-mother 1985; 28:369-374.
16. Bhavnani SM, Rubino CM, Forrest A, et al. Use of PK-PD principles to guide clinical drug development for oritavancin. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). 2008. Abstract A-51.
17. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S81-S87 (in this supplement).
18. Rubino CM, Bhavnani SM, Forrest A, Korth-Bradley J, Ambrose PG. Pharmacokinetic-pharmacodynamic analysis for efficacy of tigecycline in patients with hospital-or community-acquired pneumonia. In: Program ans abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2007. Abstract A-588.
19. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. The relationship between quinolone exposures and resistance amplification is charac-terized by an inverted-U: a new paradigm for optimizing pharmaco-dynamics to counter-select resistance. Antimicrob Agents Chemother 2007; 51:744-747.
20. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial population responses to drug selective pressure: examination of gar-enoxacin against Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-428.
21. Rubino CM, Ma L, Bhavnani SM, et al. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Anti-microb Agents Chemother 2007; 51:4085-4089.